Compare ABEO & WENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | WENN |
|---|---|---|
| Founded | 1974 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 381.2M |
| IPO Year | 2005 | N/A |
| Metric | ABEO | WENN |
|---|---|---|
| Price | $6.36 | $10.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 67.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $9.67 |
| 52 Week High | $7.54 | $10.38 |
| Indicator | ABEO | WENN |
|---|---|---|
| Relative Strength Index (RSI) | 68.60 | 55.09 |
| Support Level | $5.19 | $10.15 |
| Resistance Level | N/A | $10.37 |
| Average True Range (ATR) | 0.25 | 0.01 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 97.81 | 20.00 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Wen Acquisition Corp is a blank check company.